000181903 001__ 181903
000181903 005__ 20240229145700.0
000181903 0247_ $$2doi$$a10.1016/j.euo.2022.08.005
000181903 0247_ $$2pmid$$apmid:36175281
000181903 0247_ $$2altmetric$$aaltmetric:136684814
000181903 037__ $$aDKFZ-2022-02293
000181903 041__ $$aEnglish
000181903 082__ $$a610
000181903 1001_ $$aSaner, Yasemin Melisa$$b0
000181903 245__ $$aDetection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial.
000181903 260__ $$aAmsterdam$$bElsevier$$c2023
000181903 3367_ $$2DRIVER$$aarticle
000181903 3367_ $$2DataCite$$aOutput Types/Journal article
000181903 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1676294125_32049
000181903 3367_ $$2BibTeX$$aARTICLE
000181903 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181903 3367_ $$00$$2EndNote$$aJournal Article
000181903 500__ $$a#LA:E010# / 2023 Feb;6(1):49-55
000181903 520__ $$aMultiparametric magnetic resonance imaging (mpMRI) and targeted biopsy (TB) facilitate accurate detection of clinically significant prostate cancer (csPC). However, it remains unclear how targeted cores should be applied for accurate diagnosis of csPC.To assess csPC detection rates for two target-directed MRI/transrectal ultrasonography (TRUS) fusion biopsy approaches, conventional TB and target saturation biopsy (TS).This was a prospective single-center study of outcomes for transperineal MRI/TRUS fusion biopsies for 170 men. Half of the men (n = 85) were randomized to conventional TB with four cores per lesion and half (n = 85) to TS with nine cores. Biopsies were performed by three experienced board-certified urologists.PC and csPC (International Society of Urological Pathology grade group ≥2) detection rates for systematic biopsy (SB), TB, and TS were analyzed using McNemar's test for intrapatient comparisons and Fisher's exact test for TS versus TB. A combination of targeted biopsy (TS or TB) and SB served as the reference.According to the reference, csPC was diagnosed for 57 men in the TS group and 36 men in the TB group. Of these, TS detected 57/57 csPC cases and TB detected 33/36 csPC cases (p = 0.058). Detection of Gleason grade group 1 disease was 10/12 cases with TS and 8/17 cases with TB (p = 0.055). In addition, TS detected 97% of 63 csPC lesions, compared to 86% with TB (p = 0.1). Limitations include the single-center design, the limited generalizability owing to the transperineal biopsy route, the lack of central review of pathology and radical prostatectomy correlation, and uneven distributions of csPC prevalence, Prostate Imaging-Reporting and Data System (PI-RADS) 5 lesions, men with two or more PI-RADS ≥3 lesions, and prostate-specific antigen density between the groups, which may have affected the results.In our study, rates of csPC detection did not significantly differ between TS and TB.In this study, we investigated two targeted approaches for taking prostate biopsy samples after observation of suspicious lesions on prostate scans. We found that the rates of detection of prostate cancer did not significantly differ between the two approaches.
000181903 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000181903 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181903 650_7 $$2Other$$aDetection accuracy
000181903 650_7 $$2Other$$aFusion biopsy
000181903 650_7 $$2Other$$aMagnetic resonance imaging
000181903 650_7 $$2Other$$aProstate cancer
000181903 650_7 $$2Other$$aTarget saturation
000181903 650_7 $$2Other$$aTargeted biopsy
000181903 650_7 $$2Other$$aTransrectal ultrasound
000181903 7001_ $$0P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aWiesenfarth, Manuel$$b1$$udkfz
000181903 7001_ $$0P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6$$aWeru, Vivienn$$b2$$udkfz
000181903 7001_ $$aLadyzhensky, Boris$$b3
000181903 7001_ $$aTschirdewahn, Stephan$$b4
000181903 7001_ $$aPüllen, Lukas$$b5
000181903 7001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b6$$udkfz
000181903 7001_ $$aReis, Henning$$b7
000181903 7001_ $$aKrafft, Ulrich$$b8
000181903 7001_ $$aHeß, Jochen$$b9
000181903 7001_ $$aKesch, Claudia$$b10
000181903 7001_ $$aDarr, Christopher$$b11
000181903 7001_ $$aForsting, Michael$$b12
000181903 7001_ $$aWetter, Axel$$b13
000181903 7001_ $$aUmutlu, Lale$$b14
000181903 7001_ $$aHaubold, Johannes$$b15
000181903 7001_ $$aHadaschik, Boris$$b16
000181903 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b17$$eLast author$$udkfz
000181903 773__ $$0PERI:(DE-600)2945338-0$$a10.1016/j.euo.2022.08.005$$gp. S2588931122001456$$n1$$p49-55$$tEuropean urology oncology$$v6$$x2588-9311$$y2023
000181903 909CO $$ooai:inrepo02.dkfz.de:181903$$pVDB
000181903 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1042737c83ba70ec508bdd99f0096864$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000181903 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7dc85735e114a4ace658ba1450a2cca6$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000181903 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000181903 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000181903 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000181903 9141_ $$y2022
000181903 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL ONCOL : 2022$$d2023-08-25
000181903 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000181903 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000181903 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000181903 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000181903 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000181903 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR UROL ONCOL : 2022$$d2023-08-25
000181903 9202_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000181903 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000181903 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x1
000181903 980__ $$ajournal
000181903 980__ $$aVDB
000181903 980__ $$aI:(DE-He78)C060-20160331
000181903 980__ $$aI:(DE-He78)E010-20160331
000181903 980__ $$aUNRESTRICTED